Stuart Fine

Fundraising? Nail Your “Use of Funds” Story Many founders fumble here: They raise $500k but can’t explain exactly how they’ll use it. Investors want to know: ✅ How much will go to growth? ✅ How much for product development? ✅ What milestones will this funding unlock? Your “use of funds” isn’t just a slide in your deck. It’s a reflection of your priorities and execution plan. Clarity here = confidence from investors. Before you pitch, ask yourself: “Can I explain exactly how every dollar raised will drive us forward?” Founders, how did you allocate your last funding round? Let’s learn from each other. #FinArchitect #InvestorReady #StartupFunding #FounderTips #VCInsights

6

3 Comments

✋ It wasn't us - honest truth! It was not by AMS's design or request that an article (p16) that promotes a legacy technology for removing carcinogenic hexavalent chromium but that includes both an image of the trucks that would be required to transport weekly thousands of gallons toxic waste from dozens of local communities to specialized treatment sites and also a 'health warning' from Ecolab that the technology may also generate radioactive waste was placed alongside a fact-based article (page 19) that compares competing treatment technologies. That article systematically addresses why these legacy technologies are not fit for pupose. This also calls into serious question why some leading consulting engineers continue to promote these legacy technologies rather than offering Californian communities the option of an approved and proven solution that has a 40% lower lifetime cost. Thank you CA-NV AWWA for giving us a voice to address this situation which risks imposing unacceptable and avoidable costs on 5 million Californian consumers, many of whom live in underserved communities and who depend on water contaminated by hexavalent chromium. #gatekeepers #barrierstoinnovation #safedrinkingwater https://lnkd.in/gdr_Xjub

15

I had a conversation with Karl Schmieder, MS MFA on how #radicalcollaboration is needed to bring a bio-manufacturing industry to life. We talked about: Why invention alone isn’t enough: Discovery is no longer the bottleneck—industrial scaling, regulation, and consumer adoption are. The new role of orchestrators: The most valuable companies will be those that coordinate across supply chains, regulators, and corporates, turning fragmented players into functioning ecosystems. What this means for founders and investors: The future winners in biotech may not be those with the most novel science, but those who master the art of integration. https://lnkd.in/g4bshddA Kylie Porter Michele Stansfield David Weiner David Kestenbaum Mark Warner Sam Perkins Ian O'Hara Arturo Elizondo James Petrie Jim Fader Paul Riley Ed Husic MP Robyn Denholm Guy Reypert Chris Liu Rob Brown Emerald Scofield Dirk van der Kley

47

5 Comments